Tirofiban - Merck & Co

Drug Profile

Tirofiban - Merck & Co

Alternative Names: Aggrastat; L 462; L 700462; MK 0383; MK 383; Tirofiban HCl; Tirofiban hydrochloride

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer 4P Therapeutics; Aspen Pharmacare; Cardiome Pharma; Eddingpharm; Medicure
  • Class Antiplatelets; Aromatic amino acids; Ischaemic heart disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris
  • No development reported Coronary artery restenosis

Most Recent Events

  • 17 Jul 2017 Registered for Myocardial infarction in Canada (IV)
  • 16 Feb 2017 Tirofiban is available for licensing as of 16 Feb 2017. http://cardiome.ca/partners/ (Cardiome Pharma pipeline, February 2017)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top